Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Mixture of (R,S,S) and (S,R,R) Edoxaban Isomer Impurities

● In Stock

Catalogue No.:	VE0025815
CAS No.:	N/A
Mol. Formula:	C24H30ClN7O4S : C24H30ClN7O4S
Mol. Weight:	548.06 : 548.06 g/mol

Request a quote

Add to RFQ list

Additional information on Mixture of (R | S | S) and (S | R | R) Edoxaban Isomer Impurities

Parent drug

Edoxaban

IUPAC Name

N1-(5-chloropyridin-2-yl)-N2-((1R,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide compound with N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4R)-4-(dimethylcarbamoyl)-2-(6-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide (1:1)

Pharmacopeial Synonyms

N/A

Smiles

CN1CCC2=C(SC(C(N[C@@H]3[C@H](NC(C(NC4=CC=C(Cl)C=N4)=O)=O)CC[C@H](C(N(C)C)=O)C3)=O)=N2)C1.CN5CCC6=C(SC(C(N[C@H]7[C@@H](NC(C(NC8=CC=C(Cl)C=N8)=O)=O)CC[C@@H](C(N(C)C)=O)C7)=O)=N6)C5

InChI

InChI=1S/2C24H30ClN7O4S/c2*1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h2*5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t2*13-,15+,17-/m10/s1

Synonyms

N/A

Other Synonyms

N/A

Description

Mixture of (R,S,S) and (S,R,R) Edoxaban isomer impurities represents a chiral impurity standard intended for analytical identification and quantification in API and formulation development. Characterized by chiral HPLC, NMR, and high-resolution mass spectrometry, this isomeric pair enables validation of impurity profiles, method specificity, and stability-indicating assays. Control of these stereochemical impurities is critical for regulatory compliance and risk assessment due to potential effects on pharmacological activity and safety. Provided with certificate of analysis and recommended storage conditions, the material supports method development, forced-degradation studies, and batch release testing to ensure consistent impurity monitoring throughout the drug lifecycle.